Rescue of Mutant CFTR Channel Activity by Investigational Co-Potentiator Therapy

Overview

Journal Biomedicines

Date 2025 Jan 25

PMID 39857666

Authors

Mafalda Bacalhau

Filipa C Ferreira

Marcelo Folhadella M F Azevedo

Talita P Rosa

Camilla D Buarque

Miqueias Lopes-Pacheco

Affiliations

Soon will be listed here.

Abstract

The potentiator VX-770 (ivacaftor) has been approved as a monotherapy for over 95 cystic fibrosis (CF)-causing variants associated with gating/conductance defects of the CF transmembrane conductance regulator (CFTR) channel. However, despite its therapeutic success, VX-770 only partially restores CFTR activity for many of these variants, indicating they may benefit from the combination of potentiators exhibiting distinct mechanisms of action (i.e., co-potentiators). We previously identified , a hydroxy-1,2,3-triazole-based compound, as a modest potentiator of p.Arg334Trp-CFTR, a variant with a conductance defect for which no modulator therapy is currently approved. We synthesized a new set of LSO-24 structure-based compounds, screened their effects on p.Arg334Trp-CFTR activity, and assessed the additivity of hit compounds to VX-770, ABBV-974, ABBV-3067, and apigenin. After validation by electrophysiological assays, the most promising hits were also assessed in cells expressing other variants with defective gating/conductance, namely p.Pro205Ser, p.Ser549Arg, p.Gly551Asp, p.Ser945Leu, and p.Gly1349Asp. We found that five compounds were able to increase p.Arg334Trp-CFTR activity with similar efficacy, but slightly greater potency promoted by LSO-150 and LSO-153 (EC: 1.01 and 1.26 μM, respectively). These two compounds also displayed a higher rescue of p.Arg334Trp-CFTR activity in combination with VX-770, ABBV-974, and ABBV-3067, but not with apigenin. When tested in cells expressing other CFTR variants, LSO-24 and its derivative LSO-150 increased CFTR activity for the variants p.Ser549Arg, p.Gly551Asp, and p.Ser945Leu with a further effect in combination with VX-770 or ABBV-3067. No potentiator was able to rescue CFTR activity in p.Pro205Ser-expressing cells, while p.Gly1349Asp-CFTR responded to VX-770 and ABBV-3067 but not to LSO-24 or LSO-150. Our data suggest that these new potentiators might share a common mechanism with apigenin, which is conceivably distinct from that of VX-770 and ABBV-3067. The additive rescue of p.Arg334Trp-, p.Ser549Arg-, p.Gly551Asp-, and p.Ser945Leu-CFTR also indicates that these variants could benefit from the development of a co-potentiator therapy.

References

Boon M, Verleden S, Bosch B, Lammertyn E, McDonough J, Mai C . Morphometric Analysis of Explant Lungs in Cystic Fibrosis. Am J Respir Crit Care Med. 2015; 193(5):516-26. DOI: 10.1164/rccm.201507-1281OC. View

Laselva O, Bartlett C, Gunawardena T, Ouyang H, Eckford P, Moraes T . Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator. Eur Respir J. 2020; 57(6). PMC: 8209484. DOI: 10.1183/13993003.02774-2020. View

Volkova N, Moy K, Evans J, Campbell D, Tian S, Simard C . Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries. J Cyst Fibros. 2019; 19(1):68-79. DOI: 10.1016/j.jcf.2019.05.015. View

Liu F, Zhang Z, Levit A, Levring J, Touhara K, Shoichet B . Structural identification of a hotspot on CFTR for potentiation. Science. 2019; 364(6446):1184-1188. PMC: 7184887. DOI: 10.1126/science.aaw7611. View

Cai Z, Taddei A, Sheppard D . Differential sensitivity of the cystic fibrosis (CF)-associated mutants G551D and G1349D to potentiators of the cystic fibrosis transmembrane conductance regulator (CFTR) Cl- channel. J Biol Chem. 2005; 281(4):1970-7. DOI: 10.1074/jbc.M510576200. View

Bompadre S, Sohma Y, Li M, Hwang T . G551D and G1349D, two CF-associated mutations in the signature sequences of CFTR, exhibit distinct gating defects. J Gen Physiol. 2007; 129(4):285-98. PMC: 2151620. DOI: 10.1085/jgp.200609667. View

Lopes-Pacheco M, Pedemonte N, Veit G . Discovery of CFTR modulators for the treatment of cystic fibrosis. Expert Opin Drug Discov. 2021; 16(8):897-913. DOI: 10.1080/17460441.2021.1912732. View

Rauscher R, Bampi G, Guevara-Ferrer M, Santos L, Joshi D, Mark D . Positive epistasis between disease-causing missense mutations and silent polymorphism with effect on mRNA translation velocity. Proc Natl Acad Sci U S A. 2021; 118(4). PMC: 7848603. DOI: 10.1073/pnas.2010612118. View

Riordan J, Rommens J, Kerem B, Alon N, Rozmahel R, Grzelczak Z . Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989; 245(4922):1066-73. DOI: 10.1126/science.2475911. View

10.

Baell J, Holloway G . New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem. 2010; 53(7):2719-40. DOI: 10.1021/jm901137j. View

11.

Negoda A, Hogan M, Cowley E, Linsdell P . Contribution of the eighth transmembrane segment to the function of the CFTR chloride channel pore. Cell Mol Life Sci. 2019; 76(12):2411-2423. PMC: 11105405. DOI: 10.1007/s00018-019-03043-2. View

12.

Phuan P, Tan J, Rivera A, Zlock L, Nielson D, Finkbeiner W . Nanomolar-potency 'co-potentiator' therapy for cystic fibrosis caused by a defined subset of minimal function CFTR mutants. Sci Rep. 2019; 9(1):17640. PMC: 6881293. DOI: 10.1038/s41598-019-54158-2. View

13.

Lipinski C . Lead- and drug-like compounds: the rule-of-five revolution. Drug Discov Today Technol. 2014; 1(4):337-41. DOI: 10.1016/j.ddtec.2004.11.007. View

14.

Silva I, Laselva O, Lopes-Pacheco M . Advances in Preclinical In Vitro Models for the Translation of Precision Medicine for Cystic Fibrosis. J Pers Med. 2022; 12(8). PMC: 9409685. DOI: 10.3390/jpm12081321. View

15.

Phuan P, Son J, Tan J, Li C, Musante I, Zlock L . Combination potentiator ('co-potentiator') therapy for CF caused by CFTR mutants, including N1303K, that are poorly responsive to single potentiators. J Cyst Fibros. 2018; 17(5):595-606. PMC: 6436558. DOI: 10.1016/j.jcf.2018.05.010. View

16.

Van Goor F, Yu H, Burton B, Hoffman B . Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. J Cyst Fibros. 2013; 13(1):29-36. DOI: 10.1016/j.jcf.2013.06.008. View

17.

Yu H, Burton B, Huang C, Worley J, Cao D, Johnson Jr J . Ivacaftor potentiation of multiple CFTR channels with gating mutations. J Cyst Fibros. 2012; 11(3):237-45. DOI: 10.1016/j.jcf.2011.12.005. View

18.

Van Goor F, Hadida S, Grootenhuis P, Burton B, Cao D, Neuberger T . Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A. 2009; 106(44):18825-30. PMC: 2773991. DOI: 10.1073/pnas.0904709106. View

19.

Ai T, Bompadre S, Wang X, Hu S, Li M, Hwang T . Capsaicin potentiates wild-type and mutant cystic fibrosis transmembrane conductance regulator chloride-channel currents. Mol Pharmacol. 2004; 65(6):1415-26. DOI: 10.1124/mol.65.6.1415. View

20.

Ferreira F, Amaral M, Bacalhau M, Lopes-Pacheco M . PTI-801 (posenacaftor) shares a common mechanism with VX-445 (elexacaftor) to rescue p.Phe508del-CFTR. Eur J Pharmacol. 2024; 967:176390. DOI: 10.1016/j.ejphar.2024.176390. View